What is Autosomal dominant polycystic kidney disease?
Autosomal dominant polycystic kidney disease (ADPKD) is a hereditary kidney disorder characterized by the progressive development of fluid-filled cysts in both kidneys. It is the most common inherited kidney disease, affecting approximately 1 in 400 to 1,000 people worldwide. ADPKD typically manifests in adulthood and can lead to kidney enlargement, reduced kidney function, and eventually kidney failure. The condition also affects other organs, including the liver, and can increase the risk of cardiovascular complications.
Key statistics
| Prevalence | 1 in 400–1,000 people globally |
| Age of onset | Usually 30-50 years for symptoms; cysts may appear earlier |
| Kidney failure risk | 50% of patients by age 60; 85% by age 70 |
| Population affected | Approximately 12.5 million people worldwide |
Symptoms
Common symptoms: Flank pain, high blood pressure, blood in urine, frequent urination, kidney stones, urinary tract infections, abdominal fullness, fatigue.
Many people with ADPKD remain asymptomatic for decades, with the condition often discovered incidentally during imaging studies. The most frequent early symptom is chronic or intermittent flank pain, which occurs as enlarged cystic kidneys stretch the surrounding tissues. Hypertension develops in approximately 70% of patients before kidney function declines and is often the first detectable sign of the disease.
Hematuria, or blood in the urine, affects about half of all patients and may be visible to the naked eye or detected only through laboratory testing. Patients frequently experience recurrent urinary tract infections and kidney stones, which can cause additional pain and complications. As the kidneys enlarge, patients may notice abdominal distension and a feeling of fullness. Advanced disease can cause fatigue, nausea, and decreased appetite as kidney function deteriorates.
Causes and risk factors
ADPKD follows an autosomal dominant inheritance pattern, meaning only one copy of a mutated gene is needed to cause the disease. Mutations occur in two primary genes: PKD1 (polycystic kidney disease 1) accounts for approximately 85% of cases, while PKD2 mutations cause the remaining 15%. The PKD1 gene encodes polycystin-1, and PKD2 encodes polycystin-2, proteins essential for normal kidney tubule development and function.
About 90% of cases are inherited from an affected parent, while 10% result from spontaneous new mutations. Risk factors include having a parent with ADPKD, which confers a 50% chance of inheriting the condition. PKD1 mutations typically lead to more severe disease with earlier onset of kidney failure compared to PKD2 mutations. Additional factors that may accelerate disease progression include male gender, early onset of hypertension, and frequent urinary tract infections.
Prevention
As ADPKD is a genetic condition, primary prevention is not possible. However, genetic counseling and testing can help at-risk individuals make informed reproductive decisions. Presymptomatic genetic testing is available for family members of affected individuals, though this requires careful consideration due to potential psychological and insurance implications.
Preventive measures focus on slowing disease progression and include maintaining optimal blood pressure control, staying well-hydrated, avoiding nephrotoxic medications, and promptly treating urinary tract infections. Regular monitoring allows for early intervention when complications arise. Couples with a family history of ADPKD may consider preimplantation genetic diagnosis or prenatal testing options.
Complications
Without proper management, ADPKD leads to progressive kidney enlargement and declining function, ultimately resulting in end-stage renal disease requiring dialysis or kidney transplantation. Cardiovascular complications are common and include hypertension-related heart disease and stroke. Approximately 8-10% of patients develop intracranial aneurysms, which can be life-threatening if they rupture.
Liver cysts develop in about 80% of patients, particularly women, and may cause abdominal discomfort though they rarely affect liver function. Other complications include diverticular disease, hernias due to increased abdominal pressure, and mitral valve prolapse. Chronic pain can significantly impact quality of life, while the psychological burden of progressive disease affects mental health and family dynamics.
Diagnosis
Diagnosis relies on imaging studies, family history, and genetic testing. Ultrasound remains the initial screening tool, with specific age-based criteria for cyst number and size. For at-risk individuals aged 15-39, three or more cysts in each kidney suggest ADPKD; for those 40-59, two or more cysts per kidney; and over 60, four or more cysts per kidney.
Magnetic resonance imaging (MRI) provides superior detail and can detect smaller cysts, making it valuable for younger patients or those with negative ultrasound results. Computed tomography (CT) scanning offers excellent visualization but involves radiation exposure. Laboratory tests include serum creatinine and estimated glomerular filtration rate to assess kidney function, urinalysis to detect blood or protein, and blood pressure monitoring.
Genetic testing can definitively diagnose ADPKD and distinguish between PKD1 and PKD2 mutations, providing prognostic information. This is particularly useful when imaging results are inconclusive or for family planning purposes. Additional tests may include echocardiography to evaluate for mitral valve prolapse and, in certain cases, brain imaging to screen for aneurysms.
Treatment
Treatment focuses on slowing disease progression and managing complications. Tolvaptan, a vasopressin V2 receptor antagonist, is the first FDA-approved therapy specifically for ADPKD. It slows the rate of kidney function decline and reduces kidney growth, though it requires careful monitoring for liver toxicity.
Blood pressure management is crucial, with ACE inhibitors or ARBs preferred as first-line therapy due to their kidney-protective effects. Pain management strategies include both pharmacological approaches and interventional procedures such as cyst aspiration or surgical drainage for large, symptomatic cysts. Maintaining adequate hydration helps reduce vasopressin levels, potentially slowing cyst growth.
Urinary tract infections require prompt antibiotic treatment with agents that penetrate cysts effectively, such as fluoroquinolones or trimethoprim-sulfamethoxazole. When kidney failure occurs, treatment options include hemodialysis, peritoneal dialysis, or kidney transplantation. Patients with ADPKD often make excellent transplant candidates, with outcomes comparable to other kidney diseases.
Prognosis
Prognosis varies significantly based on genetic subtype and individual factors. PKD1-related disease typically progresses faster than PKD2, with kidney failure occurring around age 56 versus 74, respectively. Overall, approximately 50% of patients reach end-stage renal disease by age 60, and 85% by age 70.
With appropriate treatment including tolvaptan, blood pressure control, and lifestyle modifications, disease progression can be slowed significantly. Kidney transplantation offers excellent long-term outcomes, with five-year survival rates exceeding 95%. Early diagnosis and proactive management have improved quality of life substantially, allowing many patients to maintain normal activities for decades. Life expectancy approaches normal when cardiovascular complications are prevented and kidney replacement therapy is available.
Quality of life
Managing ADPKD requires lifestyle adaptations that can maintain good quality of life. Regular low-impact exercise like walking, swimming, or cycling helps maintain cardiovascular health while avoiding activities that risk kidney trauma. Adequate hydration is essential—drinking 8-10 glasses of water daily helps suppress vasopressin and may slow cyst growth.
Dietary modifications include limiting sodium to control blood pressure and moderating protein intake as kidney function declines. Caffeine restriction may be beneficial as it can stimulate cyst growth. Stress management through meditation, counseling, or support groups helps cope with the psychological impact of chronic disease. Many patients continue working with workplace accommodations for medical appointments and fatigue management.
Pain management strategies include heat therapy, gentle stretching, and when necessary, prescription medications. Planning for long-term care needs, including potential dialysis or transplantation, helps reduce anxiety about the future. Staying connected with healthcare teams and patient support networks provides both medical and emotional support throughout the disease journey.
Pregnancy and fertility
ADPKD generally does not affect fertility in men or women. However, pregnancy requires careful monitoring due to increased risks of pregnancy-induced hypertension and preeclampsia. Blood pressure control becomes more challenging during pregnancy, and some medications like ACE inhibitors must be discontinued due to teratogenic risks.
Tolvaptan is contraindicated during pregnancy and breastfeeding. Women should discuss family planning with their healthcare team to optimize pre-conception health and medication management. Genetic counseling is recommended to discuss the 50% risk of transmitting ADPKD to offspring and available reproductive options.
Most women with ADPKD have successful pregnancies, though closer monitoring by both nephrology and high-risk obstetric teams is advisable. Kidney function typically returns to baseline after delivery, though some women may experience accelerated disease progression following pregnancy.
Children
Children who inherit ADPKD typically remain asymptomatic, though cysts may be detectable on imaging before symptoms develop. Routine screening of at-risk children is generally not recommended unless symptoms occur, as early knowledge can create psychological burden without therapeutic benefit.
When symptoms do occur in children, they most commonly include urinary tract infections, blood in urine, or abdominal pain. Hypertension can develop in childhood and requires prompt treatment. Growth and development are usually normal unless severe kidney dysfunction occurs, which is rare in pediatric ADPKD.
Families should focus on healthy lifestyle habits including good hydration, regular exercise, and blood pressure monitoring when children reach adolescence. Genetic counseling becomes important as children mature and begin considering their own reproductive futures.
When to see a doctor
Immediate medical attention is needed for severe flank or abdominal pain, which could indicate cyst bleeding, kidney stones, or urinary tract infection. Fever with urinary symptoms, persistent blood in urine, or sudden onset of severe headaches warrant prompt evaluation.
Routine medical care should include annual blood pressure checks and kidney function monitoring for diagnosed patients. Family members of those with ADPKD should discuss screening options with their healthcare provider, particularly if considering pregnancy or experiencing unexplained hypertension.
Regular nephrology follow-up helps optimize treatment and monitor for complications. Patients should also maintain relationships with primary care providers for overall health management and cardiovascular risk reduction.
Regional context
Specific prevalence data for ADPKD in the Caucasus region (Georgia, Armenia, Azerbaijan) and Eastern Mediterranean countries is limited. The condition appears to affect all ethnic groups relatively equally, suggesting similar prevalence rates to global estimates.
Regional healthcare systems may face challenges in accessing specialized treatments like tolvaptan or advanced imaging modalities. Establishing regional centers of excellence and telemedicine networks could improve care access. The Global Medical Journal welcomes contributions from healthcare providers in these regions to better understand local prevalence patterns and healthcare delivery challenges.
Research and clinical trials
Current research focuses on novel therapeutic targets including mTOR pathway inhibitors, CFTR modulators, and anti-inflammatory agents. Biomarker development aims to better predict disease progression and treatment response. Imaging techniques continue advancing to enable earlier detection and more precise monitoring.
Gene therapy approaches are under investigation, including CRISPR-based strategies to correct underlying genetic defects. Clinical trials are evaluating combination therapies to enhance efficacy beyond single-agent treatment. The CRISP consortium continues long-term observational studies to better understand disease natural history.
Patients can find current clinical trials through ClinicalTrials.gov, searching for “polycystic kidney disease” to identify studies accepting participants. Participating in research helps advance understanding and treatment development for future generations.
Frequently asked questions
Will I definitely develop kidney failure if I have ADPKD?
Not necessarily. While many people with ADPKD eventually develop kidney failure, the timeline varies greatly. Some patients maintain adequate kidney function into their 70s or 80s, particularly those with PKD2 mutations. Early diagnosis and proper treatment can significantly slow progression.
Is it safe for me to have children?
Most people with ADPKD can have children safely, though genetic counseling is recommended. Each child has a 50% chance of inheriting the condition. Reproductive options including preimplantation genetic diagnosis are available for those who wish to prevent transmission.
Should my family members be tested?
This depends on individual circumstances. Adult family members may benefit from genetic counseling to discuss testing options. Routine testing of children is generally not recommended unless symptoms develop, as there are limited treatment options and potential psychological impacts.
Can diet or lifestyle changes slow the disease?
Yes, certain lifestyle modifications may help slow progression. Staying well-hydrated, maintaining healthy blood pressure, exercising regularly, and avoiding kidney-damaging medications all contribute to kidney health. However, these measures complement but cannot replace medical treatment.
What are my options if I develop kidney failure?
Treatment options include hemodialysis, peritoneal dialysis, and kidney transplantation. Many people with ADPKD are excellent candidates for transplantation and can expect good long-term outcomes. Early planning and evaluation help ensure smooth transitions between treatments.
Support and resources
PKD Foundation: pkdcure.org – Comprehensive patient resources, research updates, and support networks
National Organization for Rare Disorders (NORD): rarediseases.org
Orphanet: orpha.net – International database of rare diseases
EURORDIS: eurordis.org – European rare disease advocacy
International Society of Nephrology: theisn.org – Professional nephrology resources
National Kidney Foundation: kidney.org – General kidney disease support and education
Related conditions
Autosomal recessive polycystic kidney disease
Chronic kidney disease
Hypertensive nephrosclerosis
Von Hippel-Lindau disease
Tuberous sclerosis
Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.
Cite this page
GMJ News Desk. “Autosomal dominant polycystic kidney disease.” GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/condition/autosomal-dominant-polycystic-kidney-disease/
Licensed under CC BY 4.0. Free to share with attribution to GMJ News.Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.
Was this article helpful?